Privacy statement: Your privacy is very important to Us. Our company promises not to disclose your personal information to any external company with out your explicit permission.
Packaging: airtight package for oversea shipment
Transportation: Ocean,Land,Air,Express
Supply Ability: 5000KGS monthly
Port: BEIJING,SHANGHAI,QINGDAO
MLM341 is a new type of targeted drug for myeloma. The discovery of this drug has attracted widespread attention in the medical community. Before the advent of MLM341, multiple myeloma was a nightmare for patients with this type of disease. As a breakthrough drug for myeloma, the advantages of MLM341 are mainly manifested in the following aspects: 1. Fast onset, it only takes about 1 month to take effect; 2. The effect is significant, combined with the drug, the remission rate can reach 80% Above, the complete remission rate reaches 30%~40%. 3. It has high safety and can be applied to patients with renal insufficiency and even renal failure. The curative effect is equivalent to that of patients with normal renal function and can reverse renal function; 4. MLM341-based induction therapy can significantly increase the amount of stem cells collected. And significantly speed up the collection of stem cells.
PRODUCT (S)-3-PHENYL-2-[(PYRAZIN-2-YLCARBONYL)AMINO] PROPANOIC ACID
CAS 114457-94-2
MF C14H13N3O3
MW 271.27
Product Categories : API Intermediates > Intermediate for CAS 179324-69-7
Privacy statement: Your privacy is very important to Us. Our company promises not to disclose your personal information to any external company with out your explicit permission.
Fill in more information so that we can get in touch with you faster
Privacy statement: Your privacy is very important to Us. Our company promises not to disclose your personal information to any external company with out your explicit permission.